AI assistant
Cartesian Therapeutics, Inc. — Director's Dealing 2023
Nov 15, 2023
33483_dirs_2023-11-15_5ff2af00-b9f0-4277-8ea4-07873b7b98eb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2023-11-13
Reporting Person: Sallin Aymeric (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-11-13 | Stock Option (Right to Buy) | $17.47 | D | 6410 | Disposed | 2027-06-15 | Common Stock (6410) | Direct |
| 2023-11-13 | Stock Option (Right to Buy) | $12.75 | D | 10000 | Disposed | 2028-06-14 | Common Stock (10000) | Direct |
| 2023-11-13 | Stock Option (Right to Buy) | $2.10 | D | 10000 | Disposed | 2029-06-13 | Common Stock (10000) | Direct |
| 2023-11-13 | Stock Option (Right to Buy) | $3 | D | 20000 | Disposed | 2030-06-18 | Common Stock (20000) | Direct |
| 2023-11-13 | Stock Option (Right to Buy) | $4.01 | D | 40000 | Disposed | 2031-03-29 | Common Stock (40000) | Direct |
| 2023-11-13 | Stock Option (Right to Buy) | $3.31 | D | 40000 | Disposed | 2032-01-02 | Common Stock (40000) | Direct |
| 2023-11-13 | Stock Option (Right to Buy) | $1.13 | D | 75000 | Disposed | 2033-01-01 | Common Stock (75000) | Direct |
Footnotes
F1: This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc.
F2: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger.
F3: This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger.
F4: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger.
F5: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger.
F6: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger.
F7: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $69,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.